Linked Life Data

1558774

Source:http://linkedlifedata.com/resource/pubmed/id/1558774

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1992-5-8
pubmed:abstractText
Cotrimoxazole is currently used for Pneumocystis carinii pneumonia prophylaxis in leukemic children. The former regimen of continuous administration was recently replaced by intermittent administration. The antifolic activity of cotrimoxazole could theoretically enhance that of methotrexate, also administered to leukemic children. We report on a prospective, randomized study to compare two different regimens--continuous vs. 3 days a week--of cotrimoxazole prophylaxis. The aim of the study was to evaluate the toxicity, assuming that both regimens are equally effective to prevent P. carinii pneumonia. Seventy-seven leukemic children were enrolled; 67 were evaluable, 35 from arm A (continuous), 32 from arm B (intermittent cotrimoxazole administration). The conclusion was that long-term maintenance chemotherapy with antimetabolites produced lower levels of folate but normal levels of vitamin B12 in leukemic children. This pattern did not vary between the continuous and the 3-days-a-week administration of cotrimoxazole prophylaxis. Thus it seems hypothesizable that the antimetabolic activity of methotrexate alone exceeds that of cotrimoxazole.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0888-0018
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
35-40
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
Prospective randomized comparison of toxicity of two prophylactic regimens of cotrimoxazole in leukemic children.
pubmed:affiliation
Department of Pediatrics, IRCCS Policlinico S. Matteo, Pavia, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial